Patents Assigned to Cephalon, Inc.
  • Aryl pyridazinone derivatives and their use as H3 receptor ligands
    Patent number: 8586588
    Abstract: The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: November 19, 2013
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Nadine C. Becknell, Sankar Chatterjee, Derek Dunn, Greg A. Hostetler, Robert L. Hudkins, Kurt A. Josef, Lars J. S. Knutsen, Ming Tao, Allison L. Zulli
  • Modafinil pharmaceutical compositions
    Patent number: 8580308
    Abstract: Pharmaceutical compositions comprising modafinil in the form of particles of defined size and methods for preparing same. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: November 12, 2013
    Assignee: Cephalon, Inc.
    Inventors: Craig Heacock, Alpa Parikh, Piyush Patel
  • Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
    Patent number: 8552186
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: October 8, 2013
    Assignee: Cephalon, Inc.
    Inventors: Gulzar Ahmed, Henry J. Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce D. Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph Lisko, Rong-qiang Liu, Eugen F. Mesaros, Karen L. Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak
  • Proteasome inhibitors and methods of using the same
    Patent number: 8546608
    Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: October 1, 2013
    Assignee: Cephalon, Inc.
    Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
  • Proteasome inhibitors and processes for their preparation, purification and use
    Patent number: 8541590
    Abstract: The invention provides boronic esters of Formula I wherein R1, R2, R3, and R4 are as described herein, and methods for the preparation and purification thereof.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: September 24, 2013
    Assignee: Cephalon, Inc.
    Inventor: Renee Caroline Roemmele
  • Novel Solid Forms Of Bendamustine Hydrochloride
    Publication number: 20130245086
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: May 1, 2013
    Publication date: September 19, 2013
    Applicant: Cephalon, Inc.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Substituted spirocyclic piperidine derivatives as histamine-3 (H) receptor ligands
    Patent number: 8524713
    Abstract: The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: September 3, 2013
    Assignee: Cephalon, Inc
    Inventors: Reddeppa reddy Dandu, Robert L. Hudkins, Babu G. Sundar
  • Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands
    Patent number: 8513232
    Abstract: The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: August 20, 2013
    Assignees: Cephalon, Inc., Pharmacopeia, LLC
    Inventors: Edward R. Bacon, Nadine C. Becknell, Reddeppa reddy Dandu, Lisa Guise-Zawacki, Tao Guo, Chia-yu Huang, Robert L. Hudkins, Babu G. Sundar, Ming Tao, Minglang Wu, Allison L. Zulli
  • Forms of a fused pyrrolocarbazole compound
    Patent number: 8513272
    Abstract: Alternative chemical and/or solid state forms of Compound I, processes to reproducibly make them and methods of treating patients using them.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: August 20, 2013
    Assignee: Cephalon, Inc.
    Inventors: Stephen Bierlmaier, Raymond Scott Field, R. Curtis Haltiwanger, Martin J. Jacobs, Robert E. McKean, Mehran Yazdanian, Veronique Courvoisier
  • Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
    Patent number: 8501936
    Abstract: This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: August 6, 2013
    Assignee: Cephalon, Inc.
    Inventors: Matthew A. Curry, Bruce D. Dorsey, Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros, Karen L. Milkiewicz
  • Pyrrolotriazines as ALK and JAK2 inhibitors
    Patent number: 8471005
    Abstract: The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: June 25, 2013
    Assignee: Cephalon, Inc.
    Inventors: Henry J. Breslin, Sankar Chatterjee, James L. Diebold, Bruce D. Dorsey, Derek D. Dunn, Diane E. Gingrich, Greg A. Hostetler, Robert L. Hudkins, Rachael Hunter, Kurt A. Josef, Joseph Lisko, Eugen F. Mesaros, Karen L. Milkiewicz, Gregory R. Ott, Babu G. Sundar, Jay P. Theroff, Tho Thieu, Rabindranath Tripathy, Theodore L. Underiner, Linda Weinberg, Gregory J. Wells, Craig A. Zificsak
  • Modafinil Formulations
    Publication number: 20130156825
    Abstract: The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns.
    Type: Application
    Filed: February 21, 2013
    Publication date: June 20, 2013
    Applicant: CEPHALON, INC.
    Inventor: Cephalon, Inc.
  • Bendamustine pharmaceutical compositions
    Patent number: 8461350
    Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: June 11, 2013
    Assignee: Cephalon, Inc.
    Inventors: Jason Edward Brittain, Joe Craig Franklin
  • Methods for the Sterilization of Bendamustine
    Publication number: 20130144068
    Abstract: The present application is directed to methods of sterilizing bendamustine and its pharmaceutically acceptable salt forms. Preferred sterilization methods include dry heat sterilization, gamma irradiation, and e beam radiation. Sterile pharmaceutical compositions are also described.
    Type: Application
    Filed: January 9, 2013
    Publication date: June 6, 2013
    Applicant: Cephalon, Inc.
    Inventor: Cephalon, Inc..
  • Solid forms of bendamustine hydrochloride
    Patent number: 8445524
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: May 21, 2013
    Assignee: Cephalon, Inc.
    Inventors: Robert E. McKean, Hans-Joachim Jänsch, Veronique Courvoisier
  • Method for Purifying a Fused Pyrrolocarbazole Derivative
    Publication number: 20130123499
    Abstract: The present invention relates a method for purifying a fused pyrrolocarbazole compound known as 11-isobutyl-2-methyl-8-(2-pyrimidinylamino)-2,5,6,11,12,13-hexahydro-4Hindazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one using an acid complex thereof. The present invention also relates to a crystalline form of the acid complex.
    Type: Application
    Filed: November 16, 2012
    Publication date: May 16, 2013
    Applicants: CEPHALON FRANCE, CEPHALON, INC.
    Inventors: Cephalon, Inc., Cephalon France
  • Bendamustine pharmaceutical compositions
    Patent number: 8436190
    Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: May 7, 2013
    Assignee: Cephalon, Inc.
    Inventors: Jason Edward Brittain, Joe Craig Franklin
  • Modafinil Compositions
    Publication number: 20130096345
    Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
    Type: Application
    Filed: December 6, 2012
    Publication date: April 18, 2013
    Applicant: CEPHALON, INC.
    Inventor: CEPHALON, INC.
  • Processes for the preparation of bendamustine
    Patent number: 8420829
    Abstract: New methods for the preparation of bendamustine, and the pharmaceutical salts thereof, are described. Novel compounds useful for the preparation of bendamustine are also described.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: April 16, 2013
    Assignee: Cephalon, Inc.
    Inventors: Jian Chen, Katrin Przyuski, Renee Caroline Roemmele
  • TUMOR NECROSIS FACTOR INHIBITORS
    Publication number: 20130072562
    Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.
    Type: Application
    Filed: October 18, 2012
    Publication date: March 21, 2013
    Applicants: CEPHALON, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYVANIA
    Inventors: The Trustees Of The University Of Pennsyvania, Cephalon, Inc.